Sugi Predict

Sugi Predict / Targets / KAT2A

KAT2A

Histone acetyltransferase KAT2A · Q92830 · KAT2A on Sugi Atlas →

17,818 patent compounds predicted against KAT2A, 11,721 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL765778 SCHEMBL765778 0.56 4/20
SCHEMBL360509 SCHEMBL360509 0.77 3/20
SCHEMBL764358 SCHEMBL764358 0.60 3/20
SCHEMBL382020 SCHEMBL382020 0.30 3/20
Anacardic Acid Anacardic Acid (SCHEMBL627981) 1.00 1/20
SCHEMBL300853 SCHEMBL300853 0.97 1/20
Gingkolic Acid Gingkolic Acid (SCHEMBL163525) 0.84 1/20
SCHEMBL23277 SCHEMBL23277 0.72 1/20
SCHEMBL300614 SCHEMBL300614 0.72 1/20
SCHEMBL301487 SCHEMBL301487 0.72 1/20
SCHEMBL485756 SCHEMBL485756 0.72 1/20
SCHEMBL795643 SCHEMBL795643 0.72 1/20
SCHEMBL154719 SCHEMBL154719 0.71 1/20
SCHEMBL244743 SCHEMBL244743 0.70 1/20
SCHEMBL79983 SCHEMBL79983 0.66 1/20
SCHEMBL203818 SCHEMBL203818 0.66 1/20
SCHEMBL112984 SCHEMBL112984 0.63 1/20
SCHEMBL168815 SCHEMBL168815 0.63 1/20
SCHEMBL342175 SCHEMBL342175 0.63 1/20
SCHEMBL554986 SCHEMBL554986 0.63 1/20

Clinical trials — most relevant to KAT2A by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients PHASE3UNKNOWN
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS PHASE2COMPLETED
An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab PHASE1/PHASE2RECRUITING
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma PHASE1/PHASE2COMPLETED
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis PHASE1/PHASE2RECRUITING
Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes PHASE1/PHASE2COMPLETED
Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma PHASE2COMPLETED
Relapsed and/or Refractory Non-Hodgkin Lymphoma Study PHASE2WITHDRAWN
IST Neoadjuvant Abraxane in Newly Diagnosed Breast Cancer PHASE2UNKNOWN
5-azacytidine Valproic Acid and ATRA in AML and High Risk MDS PHASE2COMPLETED
Value of Using Pioglitazone in Chronic Myeloid Leukemia Treatment PHASE2COMPLETED
Azacitidine and Entinostat in Treating Patients With Metastatic Colorectal Cancer PHASE2COMPLETED
Suberoylanilide Hydroxamic Acid in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer PHASE2COMPLETED
Chidamide Combined With Toripalimab in Sarcoma PHASE2COMPLETED
LBH589 Treatment for Refractory Clear Cell Renal Carcinoma PHASE2COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
Safety, Tolerability and Pharmacokinetics of Benfo-Oxythiamine (B-OT) in Healthy Volunteers PHASE1COMPLETED
Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndromes PHASE1COMPLETED
Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma PHASE1UNKNOWN
Panobinostat and Epirubicin in Treating Patients With Metastatic Malignant Solid Tumors PHASE1COMPLETED
Safety Study of the Histone Deacetylase Inhibitor, CHR-3996, in Patients With Advanced Solid Tumours PHASE1COMPLETED
Chemoprevention of Head and Neck Squamous Cell Carcinoma (HNSCC) With Valproic Acid EARLY_PHASE1COMPLETED
Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP and EP300 Variants. nanUNKNOWN
Effect of Exercise Gene Expression and Histone Modifications in Patients With Hemiplegia nanRECRUITING
Epigenetic Evaluation of HAT/HDAC Activity in PBMC From Patients With Clinically Isolated Syndrome nanUNKNOWN
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma nanUNKNOWN
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics nanUNKNOWN
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia nanUNKNOWN
Studying Genes in Samples From Younger Patients With Relapsed Acute Lymphoblastic Leukemia nanCOMPLETED
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a KAT2A binder may also engage these)

ProteinNameSimilarity
Q9JHD2 — 1.000 Q9JHD2 →
KAT2B Histone acetyltransferase KAT2B 1.000 landscape →
Q1LUC3 — 1.000 Q1LUC3 →
Q9JHD1 — 1.000 Q9JHD1 →
A0A0R4IXF6 — 0.998 A0A0R4IXF6 →
SMARCC2 SWI/SNF complex subunit SMARCC2 0.994 landscape →
Q6ZPS6 — 0.993 Q6ZPS6 →
Q5JCS6 — 0.993 Q5JCS6 →
PIK3C2B Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta 0.992 landscape →
SMARCC1 SWI/SNF complex subunit SMARCC1 0.991 landscape →
P97496 — 0.991 P97496 →
Q02225 — 0.991 Q02225 →
E9PUQ8 — 0.991 E9PUQ8 →
Q9Z136 — 0.991 Q9Z136 →
O60292 — 0.991 O60292 →
Q80U87 — 0.991 Q80U87 →
Q6PDG5 — 0.990 Q6PDG5 →
Q6EU10 — 0.990 Q6EU10 →
Q9Y4B4 — 0.990 Q9Y4B4 →
Q6EE22 — 0.990 Q6EE22 →
Q9XSK8 — 0.990 Q9XSK8 →
A5D794 — 0.990 A5D794 →
Q8R0S2 — 0.989 Q8R0S2 →
Q08AX9 — 0.989 Q08AX9 →
Q9XSB5 — 0.989 Q9XSB5 →
Q64398 — 0.989 Q64398 →
Q08BR4 — 0.989 Q08BR4 →
KDM2A Lysine-specific demethylase 2A 0.989 landscape →
Q93971 — 0.989 Q93971 →
TEAD4 Transcriptional enhancer factor TEF-3 0.989 landscape →